Trial Profile
A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Sep 2021
Price :
$35
*
At a glance
- Drugs Umbralisib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hairy cell leukaemia; Hodgkin's disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors TG Therapeutics Inc
- 23 Sep 2021 According to a TG Therapeutics Inc media release, data from pooled safety analysis of NCT02793583, NCT01767766, NCT03207256 and NCT03364231 studies has been published in the Blood Advances, a journal of the American Society of Hematology.
- 23 Sep 2021 Results presented in the TG Therapeutics Inc Media Release.
- 10 May 2019 Planned End Date changed from 1 Mar 2019 to 1 Dec 2019.